NYSE:LICY

Li-Cycle (LICY) Stock Price, News & Analysis

$0.70
+0.04 (+6.05%)
(As of 05/8/2024 ET)
Today's Range
$0.65
$0.73
50-Day Range
$0.36
$1.34
52-Week Range
$0.35
$6.16
Volume
2.23 million shs
Average Volume
6.84 million shs
Market Capitalization
$125.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

Li-Cycle MarketRank™ Stock Analysis

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
648.2% Upside
$5.25 Price Target
Short Interest
Healthy
9.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of Li-Cycle in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$10,304 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.05 out of 5 stars

Computer And Technology Sector

398th out of 592 stocks

Sanitary Services Industry

3rd out of 4 stocks

LICY stock logo

About Li-Cycle Stock (NYSE:LICY)

Li-Cycle Holdings Corp. engages in the lithium-ion battery resource recovery and lithium-ion battery recycling business in North America. The company offers a mix of cathode and anode battery materials, including lithium, nickel, and cobalt, as well as graphite, copper, and aluminum; and copper and aluminum metals. It also provides hub products, such as lithium carbonate, cobalt sulphate, nickel sulphate, and manganese carbonate. Li-Cycle Holdings Corp. is headquartered in Toronto, Canada.

LICY Stock Price History

LICY Stock News Headlines

Could this Tiny Biotech End Disease Forever?
Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.
Could this Tiny Biotech End Disease Forever?
Imagine a revolutionary treatment capable of editing out ANY disease. By literally "cutting" the genetic instructions that cause illness, and "pasting" in corrected DNA to restore perfect health.
Li-Cycle Provides Organizational Structure Update
Li-Cycle Holdings: Not A Buy After The Recent Run-Up
Li-Cycle Reports Full Year 2023 Results
Li-Cycle shares rally as Glencore ups investment
See More Headlines
Receive LICY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Li-Cycle and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2024
Today
5/08/2024
Next Earnings (Confirmed)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Sanitary services
Sub-Industry
N/A
Fax
N/A
Employees
384
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.25
High Stock Price Target
$8.00
Low Stock Price Target
$0.75
Potential Upside/Downside
+688.9%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-138,000,000.00
Net Margins
-754.10%
Pretax Margin
-753.55%

Debt

Sales & Book Value

Annual Sales
$18.30 million
Book Value
$2.11 per share

Miscellaneous

Free Float
147,421,000
Market Cap
$119.18 million
Optionable
Optionable
Beta
1.52
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

LICY Stock Analysis - Frequently Asked Questions

Should I buy or sell Li-Cycle stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Li-Cycle in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LICY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LICY, but not buy additional shares or sell existing shares.
View LICY analyst ratings
or view top-rated stocks.

What is Li-Cycle's stock price target for 2024?

4 analysts have issued 1-year price objectives for Li-Cycle's shares. Their LICY share price targets range from $0.75 to $8.00. On average, they expect the company's share price to reach $5.25 in the next twelve months. This suggests a possible upside of 648.2% from the stock's current price.
View analysts price targets for LICY
or view top-rated stocks among Wall Street analysts.

How have LICY shares performed in 2024?

Li-Cycle's stock was trading at $0.5848 at the beginning of the year. Since then, LICY shares have increased by 20.0% and is now trading at $0.7017.
View the best growth stocks for 2024 here
.

Are investors shorting Li-Cycle?

Li-Cycle saw a decrease in short interest in March. As of March 31st, there was short interest totaling 11,910,000 shares, a decrease of 40.7% from the March 15th total of 20,080,000 shares. Based on an average daily trading volume, of 8,310,000 shares, the days-to-cover ratio is currently 1.4 days. Approximately 9.9% of the shares of the company are sold short.
View Li-Cycle's Short Interest
.

When is Li-Cycle's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LICY earnings forecast
.

How can I listen to Li-Cycle's earnings call?

Li-Cycle will be holding an earnings conference call on Friday, May 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Li-Cycle's earnings last quarter?

Li-Cycle Holdings Corp. (NYSE:LICY) announced its earnings results on Friday, March, 15th. The company reported $0.38 EPS for the quarter. The company earned $6.40 million during the quarter, compared to the consensus estimate of $3.53 million. Li-Cycle had a negative net margin of 754.10% and a negative trailing twelve-month return on equity of 13.33%.

Who are Li-Cycle's major shareholders?

Li-Cycle's stock is owned by many different retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.04%), Allspring Global Investments Holdings LLC (0.04%), Aaron Wealth Advisors LLC (0.04%), Mirae Asset Global Investments Co. Ltd. (0.03%), Oak Harbor Wealth Partners LLC (0.03%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Carl Deluca, Christopher J Biederman, Debbie Simpson, Mark Wellings and Timothy Johnston.
View institutional ownership trends
.

How do I buy shares of Li-Cycle?

Shares of LICY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:LICY) was last updated on 5/8/2024 by MarketBeat.com Staff

From Our Partners